W. Hanna

发表

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial

T. Owonikoko, P. Roberts, J. Hamm, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

von Willebrand's disease and arteriosclerosis

F. Rawson, P. Painter, W. Hanna, 1993, American journal of hematology.

Prevalence of Hepatitis A Antibodies in Hemophiliacs: Preliminary Results from the Southeastern Delta Hepatitis Study

S. Lemon, R. Royce, P. Rathouz, 1994, Vox sanguinis.

Treatment of von Willebrand disease with a high-purity factor VIII/von Willebrand factor concentrate: a prospective, multicenter study.

P. Mannucci, C. Kessler, B. Ewenstein, 2002, Blood.

The use of intermediate and high purity factor VIII products in the treatment of von Willebrand disease.

R. Bona, F. Rickles, W. Hanna, 1994, Thrombosis and haemostasis.

Alterations of serum and urinary carnitine profiles in cancer patients: hypothesis of possible significance.

W. L. Dodson, S. Krauss, D. S. Sachan, 1989, Journal of the American College of Nutrition.

Myelopreservation with the CDK4/6 inhibitor trilaciclib in patients with small-cell lung cancer receiving first-line chemotherapy: a phase Ib/randomized phase II trial.

T. Owonikoko, P. Roberts, J. Hamm, 2019 .

A Study of a Caucasian Family with Variant von Willebrand’s Disease in Association with Vascular Telangiectasia and Haemoglobinopathy

T. McDonald, C. Congdon, R. Lange, 1984, Thrombosis and Haemostasis.

Variant von Willebrand's disease and pregnancy.

T. McDonald, R. Lange, P. Painter, 1981, Blood.

Radioimmunoassay of fragment E‐related neoantigen: validation studies and clinical application

J. P. Chen, S. Krauss, T. Williams, 1984, British journal of haematology.

Renal disease after mitomycin c therapy

W. Murphy, S. Krauss, R. Regester, 1981, Cancer.

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Preliminary Report of a Multicenter Prospective Phase II Study of DA-EPOCH-R

W. Wilson, S. Steinberg, P. Bierman, 2015 .

Activated Factor IX Complex in Treatment of Surgical Cases of Hemophilia A with Inhibitors

R. Madigan, R. Lange, R. Lange, 1981, Thrombosis and Haemostasis.

Analysis of the relationship of von Willebrand disease (vWD) and hereditary hemorrhagic telangiectasia and identification of a potential type IIA vWD mutation (IIe865 to Thr).

F. Collins, M. Boehnke, M. Iannuzzi, 1991, American journal of human genetics.

Acute compartment syndrome in hemophilia. A case report.

R. Madigan, W. Hanna, S. Wallace, 1981, The Journal of bone and joint surgery. American volume.

Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study

J. Subramanian, T. Owonikoko, L. Hart, 2020, Advances in Therapy.

A phase Ib study of cancer stem cell (CSC) pathway inhibitor BBI-608 in combination with gemcitabine and nab-paclitaxel (nab-PTX) in patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC).

T. Bekaii-Saab, B. El-Rayes, C. Li, 2016 .

Factors affecting the appearance of a pre-peak during crossed immunoelectrophoresis of factor VIII related antigen.

D. McCarroll, W. Hanna, J. Chen, 1981, Thrombosis research.

Decreased antithrombin III level associated with failure of anticoagulation.

W. Hanna, J. Chen, S. Hanna, 1982, Southern medical journal.

Multicenter Study of Risk-Adapted Therapy With Dose-Adjusted EPOCH-R in Adults With Untreated Burkitt Lymphoma.

W. Wilson, S. Steinberg, P. Bierman, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Time Course of Early Response to Chemotherapy in Non–Small Cell Lung Cancer Patients with 18F-FDG PET/CT

David W Townsend, Claude Nahmias, L. Wahl, 2007, Journal of Nuclear Medicine.

Phase II study of bortezomib in combination with rituximab, cyclophosphamide and prednisone with or without doxorubicin followed by rituximab maintenance in patients with relapsed or refractory follicular lymphoma

R. Neuwirth, D. Esseltine, F. Cabanillas, 2014, British journal of haematology.

The Potential of F-18-FDG PET in Breast Cancer. Detection of Primary Lesions, Axillary Lymph Node Metastases, or Distant Metastases.

J. Thie, K. Hubner, K F. Hubner, 2000, Clinical positron imaging : official journal of the Institute for Clinical P.E.T.

RISK‐ADAPTED THERAPY IN ADULTS WITH BURKITT LYMPHOMA: UPDATED RESULTS OF a MULTICENTER PROSPECTIVE PHASE II STUDY OF DA‐EPOCH‐R

W. Wilson, J. Friedberg, K. Dunleavy, 2017 .

Case report: 1‐deamino‐8‐D‐arginine vasopressin and cryoprecipitate in variant von Willebrand disease

Z. Ruggeri, J. Dent, T. Zimmerman, 1985 .

Bortezomib In Combination with Rituximab, Cyclophosphamide, and Prednisone with or without Doxorubicin Followed by Rituximab Maintenance In Patients with Relapsed or Refractory Follicular Lymphoma: Results of a Phase 2 Study.

R. Neuwirth, F. Cabanillas, O. O’Connor, 2010 .

Dose effect and efficacy of rFVIIa in the treatment of haemophilia patients with inhibitors: analysis from the Hemophilia and Thrombosis Research Society Registry

P. Marks, A. Angiolillo, L. Valentino, 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

A phase Ib/II study of cancer stemness inhibitor napabucasin (BB608) combined with weekly paclitaxel in advanced non-small cell lung cancer.

R. Heist, W. Edenfield, C. Li, 2016 .

Risk-Adapted Therapy in Adults with Burkitt Lymphoma: Results of NCI 9177, a Multicenter Prospective Phase II Study of DA-EPOCH-R

W. Wilson, S. Steinberg, P. Bierman, 2017 .

R. Neuwirth, D. Esseltine, F. Cabanillas, 2014, British journal of haematology.

Bleeding symptoms and laboratory correlation in patients with severe von Willebrand disease

R. Watts, E. Kraut, B. Kerlin, 2009, Haemophilia.

Phase 1b/2 trial of cancer stemness inhibitor napabucasin (NAPA) + nab-paclitaxel (nPTX) and gemcitabine (Gem) in metastatic pancreatic adenocarcinoma (mPDAC).

T. Bekaii-Saab, S. Mikhail, B. El-Rayes, 2018 .